Ilumina closes big U.K. sequencing deal


The U.K. government chooses Ilumina (ILMN +1.5%) to sequence 100,000 human genomes in a project focused on cancer, rare and infectious diseases. The pilot phase project, called Genomics England, is expected to be completed by the end of 2017.

One in 17 people are born with or will develop a rare disease in their lifetime. 80% of rare diseases have an identified genetic component.

One of the project's goals is to kickstart the development of a U.K. genomics industry and introduce the technology into its mainstream health system.

From other sites
Comments (3)
  • Dr Joseph Haluska
    , contributor
    Comments (499) | Send Message
     
    This is a landmark deal, history in the making. long $ILMN, also $PACB. This project will yield healthcare benefits for the next hundred years.
    12 Jul 2014, 03:24 AM Reply Like
  • Ron Myers
    , contributor
    Comments (255) | Send Message
     
    "One of the project's goals is to kickstart the development of a U.K. genomics industry and introduce the technology into its mainstream health system."

     

    While here in the US the same work from the project will be used by healthcare insurers to raise premiums on those expected to develop a rare disease.
    13 Jul 2014, 01:32 AM Reply Like
  • Camden
    , contributor
    Comments (1395) | Send Message
     
    Ron,
    That's what WOULD have happened. Now, that will remain illegal unless Congress repeals or greatly changes the Affordable Care Act.
    14 Jul 2014, 09:04 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs